Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ribavirin

FDA-approved product (for solution, inhalation), marketed as Copegus, Rebetol, Ribasphere and 2 more.

Registered studies
50+
Lab records
2
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Ribavirin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chronic hepatitis C virus infection
  • Cirrhosis of liver
  • Fibrosis
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antivirals for treatment of hcv infections
FDA pharmacologic class
Nucleoside Analog Antiviral FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AP01; FDA class Nucleoside Analog Antiviral

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Ribavirin, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA19.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli5.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae5.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis22.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • E. coli: measured active in 0 of 1 lab record
  • K. pneumoniae: measured active in 0 of 1 lab record
Open Ribavirin in ChEMBL Registered studies below
Show the 2 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ribavirin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection

    NCT01768286 · start 2013-01

    Registered record
    Registry ID
    NCT01768286
    Conditions
    Chronic Hepatitis C Virus
    Interventions
    LDV/SOF; RBV
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-01
    Completion
    2014-02
    Enrolment
    441

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C Virus
    InterventionLDV/SOF; RBV
    PhasePhase 3
    Registry statusCompleted

  • In Hepatitis C Patients Treated With Interferon and Ribavirin, Does Hepcidin Contribute to Treatment Induced Anaemia

    NCT01726400 · start 2012-12

    Registered record
    Registry ID
    NCT01726400
    Conditions
    Hepatitis C
    Interventions
    Pegylated interferon alpha; Ribavirin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-12
    Completion
    2014-07
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionPegylated interferon alpha; Ribavirin
    PhaseNot recorded
    Registry statusCompleted

  • A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection

    NCT01767116 · start 2012-12

    Registered record
    Registry ID
    NCT01767116
    Conditions
    Chronic Hepatitis C Infection
    Interventions
    ABT-450/r/ABT-267, ABT-333; Ribavirin; Placebo for ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-12
    Completion
    2014-08
    Enrolment
    419

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C Infection
    InterventionABT-450/r/ABT-267, ABT-333; Ribavirin; Placebo for ribavirin
    PhasePhase 3
    Registry statusCompleted

  • A Study to Evaluate Chronic Hepatitis C Infection

    NCT01716585 · start 2012-11

    Registered record
    Registry ID
    NCT01716585
    Conditions
    Chronic Hepatitis C Infection
    Interventions
    ABT-450/r/ABT-267, ABT-333; Ribavirin; Placebo for ABT-450/r/ABT-267; Placebo for ABT-333; Placebo for ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-11
    Completion
    2014-10
    Enrolment
    636

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C Infection
    InterventionABT-450/r/ABT-267, ABT-333; Ribavirin; Placebo for ABT-450/r/ABT-267; Placebo for ABT-333 +1 more
    PhasePhase 3
    Registry statusCompleted

  • A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C

    NCT01726946 · start 2012-11

    Registered record
    Registry ID
    NCT01726946
    Conditions
    Chronic Hepatitis C
    Interventions
    VX-135; ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-11
    Completion
    2014-02
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C
    InterventionVX-135; ribavirin
    PhasePhase 2
    Registry statusCompleted

  • Orange Juice Consumption in Patients With Hepatitis C

    NCT03026569 · start 2012-05

    Registered record
    Registry ID
    NCT03026569
    Conditions
    Chronic Infection
    Interventions
    Orange juice (500 mL/d)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2012-05
    Completion
    2012-09
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Infection
    InterventionOrange juice (500 mL/d)
    PhaseNot applicable
    Registry statusCompleted

  • A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)

    NCT01467479 · start 2011-12

    Registered record
    Registry ID
    NCT01467479
    Conditions
    Hepatitis C
    Interventions
    Telaprevir; Ribavirin; Pegylated Interferon Alfa-2a; Highly Active Antiretroviral Therapy (HAART)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2011-12
    Completion
    2014-02
    Enrolment
    185

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionTelaprevir; Ribavirin; Pegylated Interferon Alfa-2a; Highly Active Antiretroviral Therapy (HAART)
    PhasePhase 3
    Registry statusTerminated

  • Boceprevir/PegIFN α-2b/Riba in HCV+ Gt1 Menopausal Women, Nonresponders to PegIFN/Riba or Treatment-naives (MEN_BOC)

    NCT01457937 · start 2011-11

    Registered record
    Registry ID
    NCT01457937
    Conditions
    Chronic Hepatitis C; Menopause
    Interventions
    Pegylated Interferon, Ribavirin, Boceprevir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2011-11
    Completion
    2014-06
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C; Menopause
    InterventionPegylated Interferon, Ribavirin, Boceprevir
    PhasePhase 3
    Registry statusUnknown

  • Treating Hispanic Patients Diagnosed With Hepatitis C Using Boceprevir

    NCT01465516 · start 2011-11

    Registered record
    Registry ID
    NCT01465516
    Conditions
    Hepatitis C Infection
    Interventions
    Boceprevir
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2011-11
    Completion
    2013-12
    Enrolment
    105

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C Infection
    InterventionBoceprevir
    PhaseNot recorded
    Registry statusTerminated

  • Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks (MK-2355-005)

    NCT01371604 · start 2011-07

    Registered record
    Registry ID
    NCT01371604
    Conditions
    Hepatitis C, Chronic
    Interventions
    IDX184; Peginterferon alfa-2a (Peg-IFN); Ribavirin (RBV); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-07
    Completion
    2014-10
    Enrolment
    68

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C, Chronic
    InterventionIDX184; Peginterferon alfa-2a (Peg-IFN); Ribavirin (RBV); Placebo
    PhasePhase 2
    Registry statusCompleted

  • The Role Of Nitazoxanide, Interferon Alfa And Ribavirin In Treatment Of Hepatitis C Infected Type 2 Diabetic Patients

    NCT01770483 · start 2011-07

    Registered record
    Registry ID
    NCT01770483
    Conditions
    Hepatitis C, Chronic; DIABETES MELLITUS Type 2
    Interventions
    nitazoxanide; conventional interferon alfa; Ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-07
    Completion
    2013-03
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C, Chronic; DIABETES MELLITUS Type 2
    Interventionnitazoxanide; conventional interferon alfa; Ribavirin
    PhasePhase 4
    Registry statusCompleted

  • Epidemiological Study to Evaluate Personality Disorders in Prison Populations in Treatment for Hepatitis C

    NCT01900886 · start 2010-12

    Registered record
    Registry ID
    NCT01900886
    Conditions
    Hepatitis C, Chronic; Personality Disorders in Prison
    Interventions
    Peginterferon alfa-2a; Ribavirin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2010-12
    Completion
    2013-12
    Enrolment
    263

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C, Chronic; Personality Disorders in Prison
    InterventionPeginterferon alfa-2a; Ribavirin
    PhaseNot recorded
    Registry statusUnknown

  • Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment

    NCT01170962 · start 2010-08

    Registered record
    Registry ID
    NCT01170962
    Conditions
    Hepatitis C Virus
    Interventions
    BMS-790052; BMS-790052; Placebo; peginterferon alfa-2a; ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-08
    Completion
    2012-12
    Enrolment
    512

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C Virus
    InterventionBMS-790052; BMS-790052; Placebo; peginterferon alfa-2a +1 more
    PhasePhase 2
    Registry statusCompleted

  • Evaluation of Unipeg® for Response and Ongoing Safety in Pakistani Population

    NCT02601976 · start 2010-08

    Registered record
    Registry ID
    NCT02601976
    Conditions
    Hepatitis C
    Interventions
    Peginterferon alfa-2a; Ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-08
    Completion
    2014-09
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionPeginterferon alfa-2a; Ribavirin
    PhasePhase 4
    Registry statusCompleted

  • A Pilot Study To Evaluate the Efficacy of Response Guided Therapy of Peginterferon Alfa Plus Ribavirin in the Treatment of Patients With HCV/HBV Co-Infection

    NCT02339337 · start 2010-06

    Registered record
    Registry ID
    NCT02339337
    Conditions
    HBV/HCV Co-infection
    Interventions
    Abbreviation of treatment duration
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-06
    Completion
    Not recorded
    Enrolment
    203

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHBV/HCV Co-infection
    InterventionAbbreviation of treatment duration
    PhasePhase 4
    Registry statusCompleted